PE20120877A1 - ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS - Google Patents

ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS

Info

Publication number
PE20120877A1
PE20120877A1 PE2011001751A PE2011001751A PE20120877A1 PE 20120877 A1 PE20120877 A1 PE 20120877A1 PE 2011001751 A PE2011001751 A PE 2011001751A PE 2011001751 A PE2011001751 A PE 2011001751A PE 20120877 A1 PE20120877 A1 PE 20120877A1
Authority
PE
Peru
Prior art keywords
hvr
sequence
seq
immunoconjugates
variant
Prior art date
Application number
PE2011001751A
Other languages
English (en)
Inventor
Kristi Elkins
Andrew Polson
Allen Ebens
Camelia Adams
Bing Zheng
Jagath R Junutula
Jo-Anne S Hongo
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120877A1 publication Critical patent/PE20120877A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

REFERIDA A UN ANTICUERPO ANTI-FcRH5 QUE COMPRENDE: a) UNA SECUENCIA DE HVR SELECCIONADA DEL GRUPO: i) HVR-L1 DE SECUENCIA KASQNVGSNVA (SEQ ID NO:28), ii) HVR-L2 DE SECUENCIA SASYRYS (SEQ ID NO:29), iii) HVR-L3 DE SECUENCIA QQYKTWT (SEQ ID NO:30), iv) HVR-H1 DE SECUENCIA GYTFTNYGMN (SEQ ID NO:37), v) HVR-H2 DE SECUENCIA NTYTGEPTYTDDFKG (SEQ ID NO:38), vi) HVR-H3 DE SECUENCIA ARRSIPYYYAMDY (SEQ ID NO:39) Y b) UNA VARIANTE DE HVR, DONDE LA VARIANTE DE HVR COMPRENDE LA MODIFICACION DE UN RESIDUO DE LA SECUENCIA SEQ ID NO:28, 29, 30, 37, 38 O 39. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA Y A UN COMPUESTO CONJUGADO
PE2011001751A 2009-04-01 2010-03-31 ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS PE20120877A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21175409P 2009-04-01 2009-04-01
US16621409P 2009-04-02 2009-04-02

Publications (1)

Publication Number Publication Date
PE20120877A1 true PE20120877A1 (es) 2012-08-06

Family

ID=42236394

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001751A PE20120877A1 (es) 2009-04-01 2010-03-31 ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS

Country Status (19)

Country Link
US (2) US8362213B2 (es)
EP (1) EP2414395A1 (es)
JP (2) JP6099976B2 (es)
KR (1) KR20120003478A (es)
CN (1) CN102369218B (es)
AR (1) AR076030A1 (es)
AU (1) AU2010232682A1 (es)
BR (1) BRPI1012560A2 (es)
CA (1) CA2756988A1 (es)
CL (1) CL2011002418A1 (es)
HK (1) HK1166805A1 (es)
IL (1) IL215404A0 (es)
MX (1) MX2011010265A (es)
PE (1) PE20120877A1 (es)
RU (2) RU2016110891A (es)
SG (1) SG174930A1 (es)
TW (1) TW201039846A (es)
WO (1) WO2010114940A1 (es)
ZA (1) ZA201107128B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
KR102030856B1 (ko) * 2011-05-27 2019-10-10 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
KR20150115000A (ko) * 2013-02-08 2015-10-13 아이알엠 엘엘씨 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
RU2668560C2 (ru) 2013-03-29 2018-10-02 Сумитомо Дайниппон Фарма Ко., Лтд. Конъюгированная вакцина на основе пептида антигена wt1
AU2014299561B2 (en) * 2013-06-24 2017-06-08 Ablbio Antibody-drug conjugate having improved stability and use thereof
TWI725931B (zh) * 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
JP7174522B2 (ja) 2014-12-05 2022-11-17 メモリアル スローン ケタリング キャンサー センター Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
AR104987A1 (es) * 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
MY189840A (en) * 2015-06-16 2022-03-11 Genentech Inc Humanized and affinity matured antibodies to fcrh5 and methods of use
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN116063508A (zh) * 2015-12-04 2023-05-05 纪念斯隆-凯特琳癌症中心 靶向Fc受体样5的抗体及使用方法
WO2017188346A1 (ja) * 2016-04-27 2017-11-02 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
MX2018015683A (es) * 2016-06-17 2019-05-27 Magenta Therapeutics Inc Composiciones y métodos para el agotamiento de células.
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
KR20210079427A (ko) * 2017-06-23 2021-06-29 벨로스바이오 인코포레이티드 Ror1 항체 면역접합체
CA3072153A1 (en) * 2017-08-10 2019-02-14 Sumitomo Dainippon Pharma Co., Ltd. Antibody-drug conjugates including hemiasterlin derivative
CN111051329A (zh) * 2017-08-10 2020-04-21 大日本住友制药株式会社 哈米特林衍生物及它们的抗体药物复合物
US10766613B2 (en) * 2017-11-28 2020-09-08 Textron Innovations Inc. System and method for rotorcraft-weight-on-wheels flight state transition control
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3826678A4 (en) * 2018-07-25 2022-06-15 Northeastern University SELECTIVE SCREENING OF ANTIMICROBIAL COMPOUNDS
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020166592A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
CA3124935A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
WO2021007338A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
CA3150538A1 (en) 2019-09-11 2021-03-18 Xuanyong Lu KAZAL INHIBITOR ANTI-SERINE PROTEASE (SPIK) ANTIBODY EPITOPES
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
MX2022007613A (es) 2019-12-18 2022-07-19 Teneofour Inc Union de anticuerpos de cadena pesada a cd38.
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
WO2023201299A1 (en) * 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
TW202406571A (zh) 2022-04-13 2024-02-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE282630T1 (de) 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
US20030027985A1 (en) 1997-06-16 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
EP1235847B1 (en) 1999-11-29 2016-01-20 The Trustees of Columbia University in the City of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CA2551813C (en) 2003-12-24 2014-08-12 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP1846449A4 (en) * 2005-01-12 2009-07-08 Medarex Inc IRTA-2 ANTIBODIES AND THEIR USE
KR101103108B1 (ko) * 2005-06-20 2012-01-04 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2008109533A2 (en) * 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use

Also Published As

Publication number Publication date
EP2414395A1 (en) 2012-02-08
AU2010232682A1 (en) 2011-11-10
RU2583270C2 (ru) 2016-05-10
JP2016028052A (ja) 2016-02-25
US8362213B2 (en) 2013-01-29
US20130089497A1 (en) 2013-04-11
RU2016110891A (ru) 2018-11-27
TW201039846A (en) 2010-11-16
CN102369218B (zh) 2014-07-16
WO2010114940A1 (en) 2010-10-07
SG174930A1 (en) 2011-11-28
CA2756988A1 (en) 2010-10-07
CN102369218A (zh) 2012-03-07
CL2011002418A1 (es) 2012-03-16
AR076030A1 (es) 2011-05-11
KR20120003478A (ko) 2012-01-10
US9017951B2 (en) 2015-04-28
JP2012522513A (ja) 2012-09-27
HK1166805A1 (en) 2012-11-09
MX2011010265A (es) 2011-10-11
BRPI1012560A2 (pt) 2016-07-26
IL215404A0 (en) 2011-12-29
US20110171125A1 (en) 2011-07-14
JP6099976B2 (ja) 2017-03-29
ZA201107128B (en) 2012-12-27

Similar Documents

Publication Publication Date Title
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
NZ597251A (en) Antibodies and immunoconjugates and uses therefor
PE20141114A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
PE20090943A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
ES2628108T3 (es) Anticuerpos multiespecíficos
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20170670A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20120553A1 (es) Anticuerpos anti-fgfr3
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
WO2013003680A8 (en) Anti-c-met antibody formulations
PE20121023A1 (es) Anticuerpos e inmunoconjugados
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
PE20140771A1 (es) Anticuerpos anti-ige apoptoticos
PE20150614A1 (es) Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
CO6331344A2 (es) Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PE20160712A1 (es) Anticuerpos e inmunoconjugados anti-cd33

Legal Events

Date Code Title Description
FD Application declared void or lapsed